FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283023575> ?p ?o ?g. }

• W4283023575 endingPage "988" @default.
• W4283023575 startingPage "980" @default.
• W4283023575 abstract "BACKGROUND: Venetoclax, in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC), received confirmatory approval in 2020 by the US Food and Drug Administration for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients aged 75 years or older or who are ineligible for intensive induction chemotherapy. The economic value associated with response to venetoclax combinations compared with other treatments for this patient population has not been comprehensively evaluated. OBJECTIVE: To assess the cost per patient achieving remission with venetoclax combination therapies, compared with other therapies for newly diagnosed patients with AML who are ineligible for intensive induction chemotherapy, from a US third-party payer perspective. METHODS: The analysis used treatment effect estimates (ie, complete remission [CR] + CR with incomplete blood count recovery [CRi]) from a network meta-analysis and annual cost estimates from a prior budget impact model. The model considered the total cost of care including the costs of drug and administration, adverse events, hospitalization, disease monitoring, blood transfusions, and subsequent AML management when patients discontinued active treatment. Costs per patient achieving CR + CRi associated with venetoclax + azacitidine, venetoclax + LDAC, azacitidine, decitabine, LDAC, and best supportive care (ie, treatment given with the intent to maximize quality of life without specific antileukemic intent, such as blood transfusion products and antibiotics) were calculated as the annual total cost of care per patient divided by the CR + CRi rate. All costs were adjusted to 2020 US dollars. RESULTS: Venetoclax combination therapies were estimated to have substantially lower costs per patient achieving CR + CRi (venetoclax + azacitidine: $473,960; venetoclax + LDAC: $428,071) than alternative treatments. Azacitidine was estimated to have the the highest cost per patient achieving CR + CRi ($1,197,438), followed by best supportive care ($869,849), LDAC ($689,101), and decitabine ($594,074). A pair-wise matrix of the difference between therapies estimated that both venetoclax + azacitidine and venetoclax + LDAC were associated with significantly lower costs per patient achieving CR + CRi than azacitidine (by $723,477 and $769,367, respectively) and LDAC (by $215,141 and $261,030; all P < 0.05). CONCLUSIONS: From a US third-party payer perspective, venetoclax in combination with azacitidine or LDAC was estimated to be associated with a significantly lower cost per patient achieving CR + CRi than azacitidine or LDAC among newly diagnosed patients with AML ineligible for intensive chemotherapy. DISCLOSURES: This research was supported by AbbVie Inc. and Genentech. The sponsors helped design the study, interpret the data, and draft the manuscript. Drs Bui and Kapustyan are employees of and have equity ownership in AbbVie; Dr Choi was an employee of AbbVie during the study’s conduct and has equity ownership. Ms Ma and Dr Montez are employees of and have equity ownership in Genentech. Drs Song and Chai, Ms Yin, and Dr Betts are employees of Analysis Group, Inc., which has received funding from AbbVie and Genentech for the conduct of this research. Dr LeBlanc reports personal fees for consulting or advisory boards from AbbVie, Agios/Servier, AstraZeneca, Amgen, Astellas, BlueNote, CareVive, BMS/Celgene, Daiichi-Sankyo, Flatiron, Genentech, GSK, Pfizer, and Seattle Genetics; royalties from UpToDate; speakers bureau fees from Agios/Servier, AbbVie, and BMS/Celgene; and grants and/or research contracts from the American Cancer Society, AstraZeneca, BMS, Jazz Pharmaceuticals, and Seattle Genetics." @default.
• W4283023575 created "2022-06-18" @default.
• W4283023575 creator A5001676777 @default.
• W4283023575 creator A5012983001 @default.
• W4283023575 creator A5040432672 @default.
• W4283023575 creator A5046710013 @default.
• W4283023575 creator A5060356377 @default.
• W4283023575 creator A5062507167 @default.
• W4283023575 creator A5065311807 @default.
• W4283023575 creator A5082155253 @default.
• W4283023575 creator A5085560257 @default.
• W4283023575 creator A5090882745 @default.
• W4283023575 date "2022-09-01" @default.
• W4283023575 modified "2023-10-16" @default.
• W4283023575 title "Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy" @default.
• W4283023575 cites W1600365609 @default.
• W4283023575 cites W1842764967 @default.
• W4283023575 cites W1996383959 @default.
• W4283023575 cites W2003455709 @default.
• W4283023575 cites W2018074634 @default.
• W4283023575 cites W2065406906 @default.
• W4283023575 cites W2106084333 @default.
• W4283023575 cites W2139948141 @default.
• W4283023575 cites W2159507916 @default.
• W4283023575 cites W2165831721 @default.
• W4283023575 cites W2170075800 @default.
• W4283023575 cites W2178924775 @default.
• W4283023575 cites W2556473631 @default.
• W4283023575 cites W2790848344 @default.
• W4283023575 cites W2793886497 @default.
• W4283023575 cites W2808959793 @default.
• W4283023575 cites W2942855506 @default.
• W4283023575 cites W2995135594 @default.
• W4283023575 cites W3007005703 @default.
• W4283023575 cites W3013447738 @default.
• W4283023575 cites W3015554812 @default.
• W4283023575 cites W3030525376 @default.
• W4283023575 cites W3048827006 @default.
• W4283023575 cites W3092245026 @default.
• W4283023575 cites W3097753648 @default.
• W4283023575 cites W3157880997 @default.
• W4283023575 cites W4231346141 @default.
• W4283023575 cites W4376595466 @default.
• W4283023575 doi "https://doi.org/10.18553/jmcp.2022.22021" @default.
• W4283023575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35708343" @default.
• W4283023575 hasPublicationYear "2022" @default.
• W4283023575 type Work @default.
• W4283023575 citedByCount "0" @default.
• W4283023575 crossrefType "journal-article" @default.
• W4283023575 hasAuthorship W4283023575A5001676777 @default.
• W4283023575 hasAuthorship W4283023575A5012983001 @default.
• W4283023575 hasAuthorship W4283023575A5040432672 @default.
• W4283023575 hasAuthorship W4283023575A5046710013 @default.
• W4283023575 hasAuthorship W4283023575A5060356377 @default.
• W4283023575 hasAuthorship W4283023575A5062507167 @default.
• W4283023575 hasAuthorship W4283023575A5065311807 @default.
• W4283023575 hasAuthorship W4283023575A5082155253 @default.
• W4283023575 hasAuthorship W4283023575A5085560257 @default.
• W4283023575 hasAuthorship W4283023575A5090882745 @default.
• W4283023575 hasConcept C104317684 @default.
• W4283023575 hasConcept C126322002 @default.
• W4283023575 hasConcept C143998085 @default.
• W4283023575 hasConcept C150194340 @default.
• W4283023575 hasConcept C177713679 @default.
• W4283023575 hasConcept C185592680 @default.
• W4283023575 hasConcept C190727270 @default.
• W4283023575 hasConcept C2776239401 @default.
• W4283023575 hasConcept C2776694085 @default.
• W4283023575 hasConcept C2777938653 @default.
• W4283023575 hasConcept C2778041864 @default.
• W4283023575 hasConcept C2778336483 @default.
• W4283023575 hasConcept C2778461978 @default.
• W4283023575 hasConcept C2778729363 @default.
• W4283023575 hasConcept C2779675984 @default.
• W4283023575 hasConcept C2780235182 @default.
• W4283023575 hasConcept C2908647359 @default.
• W4283023575 hasConcept C55493867 @default.
• W4283023575 hasConcept C71924100 @default.
• W4283023575 hasConcept C99454951 @default.
• W4283023575 hasConceptScore W4283023575C104317684 @default.
• W4283023575 hasConceptScore W4283023575C126322002 @default.
• W4283023575 hasConceptScore W4283023575C143998085 @default.
• W4283023575 hasConceptScore W4283023575C150194340 @default.
• W4283023575 hasConceptScore W4283023575C177713679 @default.
• W4283023575 hasConceptScore W4283023575C185592680 @default.
• W4283023575 hasConceptScore W4283023575C190727270 @default.
• W4283023575 hasConceptScore W4283023575C2776239401 @default.
• W4283023575 hasConceptScore W4283023575C2776694085 @default.
• W4283023575 hasConceptScore W4283023575C2777938653 @default.
• W4283023575 hasConceptScore W4283023575C2778041864 @default.
• W4283023575 hasConceptScore W4283023575C2778336483 @default.
• W4283023575 hasConceptScore W4283023575C2778461978 @default.
• W4283023575 hasConceptScore W4283023575C2778729363 @default.
• W4283023575 hasConceptScore W4283023575C2779675984 @default.
• W4283023575 hasConceptScore W4283023575C2780235182 @default.
• W4283023575 hasConceptScore W4283023575C2908647359 @default.
• W4283023575 hasConceptScore W4283023575C55493867 @default.
• W4283023575 hasConceptScore W4283023575C71924100 @default.

• next